Henri Temianka Correspondence; (chirac)

This collection contains material pertaining to the life, career, and activities of Henri Temianka, violin virtuoso, conductor, music teacher, and author. Materials include correspondence, concert programs and flyers, music scores, photographs, and books.https://digitalcommons.chapman.edu/temianka_correspondence/1596/thumbnail.jp

Widening the options for recurrent malaria.

The global need for new antimalarial drugs and new combinations is enormous and urgent,1, 2 but their successful delivery needs resilience to overcome the barriers imposed by expensive and lengthy clinical development plans. Attention is often directed to areas such as southeast Asia, where some antimalarial combinations are failing but transmission intensities are much lower than in sub-Saharan African countries. Children in Africa have frequent and life-threatening malaria infections as they grow up, and these need to be treated safely

L’agrément du leadership communicationnel de Félix Antoine TSHISEKEDI TSHILOMBO à l’Union pour la Démocratie et le Progrès Social-TSHISEKEDI « UDPS-T ». Entre le mimétisme et le style personnel

Résumé : Il résulte de nos données de recherche que le président Félix Tshisekedi dispose d’un leadership communicationnel efficace qui lui a valu une adoption et une forte confiance auprès des membres de l’UDPS. Il représente un bon communicateur qui sait mettre en valeur ses compétences humaines, personnelles, sociales et morales. Son adoption est le résultat à la fois du mimétisme politique et de son style personnel. Il a su incarner les valeurs politiques de son père et il rassurait depuis lors de veiller à la continuité de son idéologie politique. Mots-clés : mimétisme, leadership, démocratie

Technologies for the functionalization of textile mats with nanoparticles

Nanotechnology is the science of materials with extremely small dimensions (one nanometer is one billionth meter), but it is a major developing industry with an estimated annual market of about one trillion US dollars by 2017[1]. Nanoparticles are used or evaluated for use in many areas, which is currently demonstrated on the market for over 1,000 nano-products. The impact of nanotechnology extends from its medical, ethical, mental, legal and environmental applications to areas such as engineering, biology, chemistry, computer science, materials science and communications [2-3]. Potential risks include environmental, health and safety issues; transient effects, such as the reallocation of traditional industries as nanotechnology products, are becoming dominant and are a cause for concern for privacy lawyers [4-5]. Textile of 100% cotton, 55% polyester / 45% cotton and 100% polyester, white and dyed, were functionalized by spraying technology on a test device made at UT Dresden after oleofobization with Rucostar EEF6 or Nuva N 2114 and impregnation by applying oleophobic treatment simultaneously with the functionalization with Ag NP. Analysis of the size and form of Ag NP was achieved by using SEM electronic microscopy, TEM and dynamic light scattering (DLS) transmission microscopy. The uniformity, dispersion and migration of Ag NP from the surface of the textile materials for the initial samples compared with those tested for acid / alkaline perspiration, washing and wear (rubbing) revealed by AAS determinations that the acidic sweat test is the most aggressive leading to decreases in the amount of Ag NP of approx. 25% versus untreated sample. The amount of Ag NP deposited on the textile by the two technologies did not differ significantly. Compared to untreated knits with treated ones the size of the agglomerations does not change significantly; from the point of view of the uniform distribution of Ag NP on the surface of the knits after the acid / alkaline sweat tests, the best values (agglomeration distances) are highlighted in the case of 100% polyester knitted

Neglected Diseases in the News: A Content Analysis of Recent International Media Coverage Focussing on Leishmaniasis and Trypanosomiasis

In recent years, there has been a flurry of activity to reverse the neglect that has characterised NTDs, mostly focussed on drug development. The drug gap may be explained by market failure, yet other forces also conspire to cause the neglect of NTDs. One problem is the low visibility of these diseases. By comparison, the high-profile “big three” infectious diseases of AIDS, tuberculosis, and malaria have received increased donor attention and funding with greater visibility. Efforts to remove the “neglect” from NTDs must involve raising their profile. This study, focussing on three of the most neglected diseases, aims to provide a context of the current media situation—the what, where, and why of NTD coverage—to support future advocacy work

Development of and Access to Products for Neglected Diseases

INTRODUCTION: Prior research on neglected disease drug development suggested inadequate funding was responsible for relatively few new approvals. In response, significantly more resources have been allocated towards development of drugs targeting neglected diseases. Our objective was to reassess drug development between 1975 and 1999, evaluate progress in neglected disease drug development since 2000, and explain how increased numbers of approvals are a necessary but insufficient condition to improving access. METHODS: To assess numbers of approvals targeting neglected diseases, we employed two distinct methodologies: First, to revisit numbers published in Trouiller et al. (2002) we used their method to count marketed new chemical entities (NCEs) between 1975 and 1999. Second, using the G-Finder report as a benchmark, we identified which diseases are currently considered "neglected" to tally approvals in the 1975-1999 and 2000-2009 periods. Searching PharmaProjects and IMS R&D Focus databases as well as websites from numerous drug regulatory agencies, we identified new drug approvals and indications. Also, we examined the World Health Organization's (WHO) Essential Drug List (EDL) to see which drugs and indications were on the list. FINDINGS: Upon recount, using Trouiller et al. methodology, we found that between 1975 and 1999 more NCEs (n = 32) targeting tropical diseases and tuberculosis were approved than reported in Trouiller et al. (n = 16). Using the G-Finder method of defining neglected diseases, we found 46 new drug approvals between 1975 and 1999. WHO included 85% of these drugs on the EDL. In the period 2000 to May 2009, despite much greater funding, only 26 new drugs and vaccines for neglected diseases were marketed. Of these, WHO placed 50% on the EDL. CONCLUSIONS: Product approvals for neglected diseases have increased, though progress has been uneven, with malaria appearing to benefit most in the short run from increased funding, while less success has been booked in other disease categories. Uneven progress suggests funding could be better targeted, particularly with regard to neglected diseases that have hitherto received scant attention. In addition, policymakers should focus on other aspects related to access. Besides drug development, there are the issues of EDL listing, architecture, availability, affordability, and adoption